BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

507 related articles for article (PubMed ID: 29258901)

  • 1. Association Between Low Plasma Level of Citrulline Before Allogeneic Hematopoietic Cell Transplantation and Severe Gastrointestinal Graft vs Host Disease.
    Hueso T; Gauthier J; Joncquel Chevalier-Curt M; Magro L; Coiteux V; Dulery R; Carpentier B; Labreuche J; Damaj G; Yakoub-Agha I; Seguy D
    Clin Gastroenterol Hepatol; 2018 Jun; 16(6):908-917.e2. PubMed ID: 29258901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Severity of acute gastrointestinal graft-vs-host disease is associated with incidence of bloodstream infection after adult allogeneic hematopoietic stem cell transplantation.
    Modi A; Rybicki L; Majhail NS; Mossad SB
    Transpl Infect Dis; 2020 Feb; 22(1):e13217. PubMed ID: 31769584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Venous thromboembolism is associated with graft-
    Kekre N; Kim HT; Ho VT; Cutler C; Armand P; Nikiforow S; Alyea EP; Soiffer RJ; Antin JH; Connors JM; Koreth J
    Haematologica; 2017 Jul; 102(7):1185-1191. PubMed ID: 28341735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood.
    Holmqvist AS; Chen Y; Wu J; Battles K; Bhatia R; Francisco L; Hageman L; Kung M; Ness E; Parman M; Salzman D; Wadhwa A; Winther JF; Rosenthal J; Forman SJ; Weisdorf DJ; Armenian SH; Arora M; Bhatia S
    JAMA Oncol; 2018 Dec; 4(12):e182453. PubMed ID: 30054602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine in combination with mycophenolate mofetil versus methotrexate for graft versus host disease prevention in myeloablative HLA-identical sibling donor allogeneic hematopoietic cell transplantation.
    Hamilton BK; Rybicki L; Dean R; Majhail NS; Haddad H; Abounader D; Hanna R; Sobecks R; Duong H; Hill BT; Copelan E; Bolwell B; Kalaycio M
    Am J Hematol; 2015 Feb; 90(2):144-8. PubMed ID: 25353395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of secondary allogeneic hematopoietic stem cell transplantation in 70 patients with recurrent hematologic malignancies after transplantation].
    Han TT; Liu Y; Chen Y; Zhang YY; Fu HX; Yan CH; Mo XD; Wang FR; Wang JZ; Han W; Chen YY; Chen H; Sun YQ; Cheng YF; Wang Y; Zhang XH; Huang XJ; Xu LP
    Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):458-464. PubMed ID: 37550200
    [No Abstract]   [Full Text] [Related]  

  • 9. Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies.
    Beckerson J; Szydlo RM; Hickson M; Mactier CE; Innes AJ; Gabriel IH; Palanicawandar R; Kanfer EJ; Macdonald DH; Milojkovic D; Rahemtulla A; Chaidos A; Karadimitris A; Olavarria E; Apperley JF; Pavlu J
    Clin Nutr; 2019 Apr; 38(2):738-744. PubMed ID: 29650256
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Partial T-cell depletion improves the composite endpoint graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic stem cell transplantation.
    Simonetta F; Masouridi-Levrat S; Beauverd Y; Tsopra O; Tirefort Y; Koutsi A; Stephan C; Polchlopek-Blasiak K; Pradier A; Dantin C; Ansari M; Roosnek E; Chalandon Y
    Leuk Lymphoma; 2018 Mar; 59(3):590-600. PubMed ID: 28679328
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of Previous Inflammatory Bowel Disease on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation: A Matched-Pair Analysis.
    Rabian F; Porcher R; Sicre de Fontbrune F; Lioure B; Laplace A; Nguyen S; Tabrizi R; Vigouroux S; Tomowiak C; Maillard N; Suarez F; Delage J; Peffault de Latour R; Socié G;
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1721-1724. PubMed ID: 27246370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gut decontamination during allogeneic hematopoietic stem cell transplantation and the risk of acute graft-versus-host disease.
    Gjærde LK; Schmidt M; Sengeløv H
    Bone Marrow Transplant; 2018 Aug; 53(8):1061-1064. PubMed ID: 29491465
    [No Abstract]   [Full Text] [Related]  

  • 13. Serum citrulline levels as a marker of enterocyte function in patients after allogeneic hematopoietic stem cells transplantation - a pilot study.
    Vokurka S; Svoboda T; Rajdl D; Sedláčková T; Racek J; Koza V; Trefil L
    Med Sci Monit; 2013 Feb; 19():81-5. PubMed ID: 23369891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ex Vivo CD34
    Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence, risk factors, and outcome of cytomegalovirus viremia and gastroenteritis in patients with gastrointestinal graft-versus-host disease.
    Bhutani D; Dyson G; Manasa R; Deol A; Ratanatharathorn V; Ayash L; Abidi M; Lum LG; Al-Kadhimi Z; Uberti JP
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):159-64. PubMed ID: 25445637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after Allogeneic Hematopoietic Stem Cell Transplantation.
    Inagaki J; Moritake H; Nishikawa T; Hyakuna N; Okada M; Suenobu S; Nagai K; Honda Y; Shimomura M; Fukano R; Noguchi M; Kurauchi K; Tanioka S; Okamura J
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1973-80. PubMed ID: 26234723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.
    Ramalingam S; Siamakpour-Reihani S; Bohannan L; Ren Y; Sibley A; Sheng J; Ma L; Nixon AB; Lyu J; Parker DC; Bain J; Muehlbauer M; Ilkayeva O; Kraus VB; Huebner JL; Spitzer T; Brown J; Peled JU; van den Brink M; Gomes A; Choi T; Gasparetto C; Horwitz M; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Sung AD
    PLoS One; 2021; 16(6):e0252995. PubMed ID: 34170918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human herpesvirus 6 reactivation on the 30th day after allogeneic hematopoietic stem cell transplantation can predict grade 2-4 acute graft-versus-host disease.
    Gotoh M; Yoshizawa S; Katagiri S; Suguro T; Asano M; Kitahara T; Akahane D; Okabe S; Tauchi T; Ito Y; Ohyashiki K
    Transpl Infect Dis; 2014 Jun; 16(3):440-9. PubMed ID: 24810656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved graft-versus-host disease-free, relapse-free survival associated with bone marrow as the stem cell source in adults.
    Mehta RS; Peffault de Latour R; DeFor TE; Robin M; Lazaryan A; Xhaard A; Bejanyan N; de Fontbrune FS; Arora M; Brunstein CG; Blazar BR; Weisdorf DJ; MacMillan ML; Socie G; Holtan SG
    Haematologica; 2016 Jun; 101(6):764-72. PubMed ID: 27036159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and risk factor of hemorrhagic cystitis after allogeneic transplantation with fludarabine, busulfan, and anti-thymocyte globulin myeloablative conditioning.
    Lam W; Storek J; Li H; Geddes M; Daly A
    Transpl Infect Dis; 2017 Jun; 19(3):. PubMed ID: 28199755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.